Travere Therapeutics (TVTX) Debt to Equity: 2013-2025
Historic Debt to Equity for Travere Therapeutics (TVTX) over the last 5 years, with Jun 2025 value amounting to $2.10.
- Travere Therapeutics' Debt to Equity was N/A to $2.10 in Q2 2025 from the same period last year, while for Jun 2025 it was $2.10, marking a year-over-year change of. This contributed to the annual value of $1.16 for FY2024, which is N/A change from last year.
- Latest data reveals that Travere Therapeutics reported Debt to Equity of $2.10 as of Q2 2025, which was up 0.35% from $2.09 recorded in Q1 2025.
- In the past 5 years, Travere Therapeutics' Debt to Equity ranged from a high of $2.10 in Q2 2025 and a low of -$2.25 during Q3 2024.
- Over the past 3 years, Travere Therapeutics' median Debt to Equity value was $0.61 (recorded in 2023), while the average stood at $0.53.
- As far as peak fluctuations go, Travere Therapeutics' Debt to Equity slumped by 70.27% in 2021, and later soared by 566.92% in 2022.
- Travere Therapeutics' Debt to Equity (Quarterly) stood at $0.02 in 2021, then spiked by 566.92% to $0.16 in 2022, then climbed by 27.16% to $0.06 in 2023, then reached $1.16 in 2024, then reached $2.10 in 2025.
- Its Debt to Equity stands at $2.10 for Q2 2025, versus $2.09 for Q1 2025 and $1.16 for Q4 2024.